Nektar Therapeutics News - NKTR

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form 144 - Report of proposed sale of securities

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar Therapeutics Reports Third Quarter 2024 Financial Results PR Newswire SAN FRANCISCO, Nov. 7, 2024 SAN...

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of...

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nektar Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN FRANCISCO, Nov. 6, 2024...

Form 8-K - Current report

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation...

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of...

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in...

MB1972 3 months ago

Any news? why the jump? anybody...

👍️0

glenn1919 3 months ago

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 3 months ago

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 4 months ago

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 5 months ago

NKTR....................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

TrendTrade2016 6 months ago

NKTR...READY TO BREAK OUT!

👍️0

glenn1919 6 months ago

NKTR............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 7 months ago

NKTR.........................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 7 months ago

NKTR new 52 week high

👍️0

Monksdream 7 months ago

NKTR under $2

👍️0

glenn1919 7 months ago

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 7 months ago

NKTR new 52 hi

👍️0

TrendTrade2016 7 months ago

NKTR here we go. Every time I go higher with my bench press this stocks follows

👍️0

TrendTrade2016 7 months ago

NKTR setting up here

👍️0

TrendTrade2016 7 months ago

NKTR...MASSIVE VOLUME

👍️0

TrendTrade2016 7 months ago

NKTR...PUSHING TO THE TOP OF THE WEEKLY CLOUD....WILL SHE BREAK FOR BLUE SKY!!!

👍️0

glenn1919 7 months ago

NKTR........................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 7 months ago

NKTR new 52 hi

👍️0

Monksdream 8 months ago

NKTR new 52 hi

👍️0

glenn1919 8 months ago

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

Awl416 9 months ago

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

👍️0

glenn1919 9 months ago

NKTR.......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 9 months ago

NKTR 10Q March 4

👍️0

Monksdream 1 year ago

NKTR new 52 week low

👍️0

Monksdream 1 year ago

NKTR new 52 week low

👍️0

seve333 1 year ago

Stock is in the toilet again they need an actual settlement from LLY go get the stock moving and so far crickets.

👍️0

sc00pnDump 1 year ago

Nice stock options 0.68 @ 85,000 shares

👍️0

81vette 1 year ago

Holding up amazingly well,might continue up

👍️0

Invest-in-America 1 year ago

NKTR: Now suing Eli Lilly, in conjunction with today's earlier (Dermatitis) news package.

👍️0

Invest-in-America 1 year ago

NKTR: This one ain't over until the FAT PHARMACISTS sing!!

👍️0

Invest-in-America 1 year ago

NKTR: Huge numbers of Peeps MISSED your brilliant pick here today, Dude!!! (Talk about 'easy money'!!)

👍️0

AJ Freely 1 year ago

$NKTR - 👆Up 15.8% Pre-Market/ Current Price $0.61
Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in '22 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

👍️0

The Night Stalker 1 year ago

cheap

👍️0

The Night Stalker 1 year ago

cheap

👍️0

DavidTrader 2 years ago

pincher chart on the daily and weekly, I think this could easily run to $1.50

👍️0

Lilman72003 2 years ago

Hmmm just crickets around here, I don’t mind arriving early to the party

👍️0

DewDiligence 3 years ago

NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures in RCC and bladder cancer:

https://finance.yahoo.com/news/nektar-bristol-myers-squibb-announce-203000621.html Nektar Therapeutics and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued. Bempeg previously failed in a phase-3 trial in combination with Opdivo in melanoma (#msg-168191364), so today’s news is three strikes and you’re out!

Rarely has a cancer drug failed so utterly and completely to live up to initial expectations (#msg-138532013). NKTR’s share price is down 96%(!) from its 2018 high.

👍️0

Frankestin 3 years ago

Ouch Ouch
how it hurts here!
I don't even see a reason to hope it goes up!
How much cash do they have?
But that's enough until the end of 2024 if that's okay ...
THE MANAGER OF NEKTAR THERAPEUTICS SAYS TO PREPARE A PLAN THAT HAS THE OBJECTIVE OF ESTABLISHING THE MINIMUM CASH TRACK UNTIL AT LEAST 2024 - CONF. CALL
As the drug fails to meet any of its goals, Nektar said he would consider curbing his cash spending, which was about $ 800 million at the end of December.

Last week, brokerage agency Oppenheimer estimated that worldwide un-risk-adjusted bempegaldesleukin sales could reach $ 3.7 billion in 2038. (news)

I know of one recently approved that will do 3B by 2026

👍️0

DewDiligence 3 years ago

NKTR’s Bempeg fails as addend to Opdivo in first-line melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-nektar-announce-105900961.html Bristol Myers Squibb and Nektar Therapeutics today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.

Given there was no additional clinical benefit in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint.

Additionally, based on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma.

👍️0

DewDiligence 4 years ago

NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer:

https://finance.yahoo.com/news/nektar-announces-agreement-phase-2-130000352.html

NKTR is receiving no cash from MRK—only free drug for use in the trial. Rather, unding for the trial is being provided by NKTR’s financing deal with SJC Pharma (https://finance.yahoo.com/news/nektar-announces-collaboration-sfj-pharmaceuticals-125900283.html ).

Note that the 3-year PD-(L)1 exclusivity period of the BMY/NKTR collaboration, which was announced on 2/14/18, has now expired, enabling NKTR to test Bempeg with any PD-(L)1 agent of its choosing.

p.s. Even after today’s pop, NKTR’s share price is down about 70% from the day of the BMY announcement three years ago.

👍️0

ClayTrader 5 years ago

* * $NKTR Video Chart 01-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

DewDiligence 5 years ago

Comments on the JPM webcast: #msg-153299506.

👍️0

DewDiligence 5 years ago

We talk about NKTR a little on #board-1418.

👍️0

Sluicebox 5 years ago

On what board are people discussing Nektar ?

👍️0

czni 5 years ago

Yea, bloody taa for !?
I will check back. Those were shot down before I could focus on them. It’s just that one ticker.
A big pharm company is going to buy 11% of a biotech company.
Whatever you do
Find it.
Two day jump could mean over 50% growth before all the old-timers start jumping out because they were holding this in 1912. BC :)
Im an old timer so I can say this.
Dont miss this one!
And please dont let me miss.
I have an entire day on this :(

Once we are free of that, all of the new people will be coming in by Thursday.

Come on people? It’s really important.

👍️0

czni 5 years ago

Well if that wasn’t the strangest thing on the planet?

My plan was to research the heck out of this thing and share it with who is on this weekend.

This way we can start Monday ahead of the pac.

There really are only two questions that I would like answers to. This company of course and it’s future and of course what my other message said. Much obliged and whatever I find out, it stays right here.

👍️0

czni 5 years ago

I have been doing a lot of studying on this company. I know that we are closer to the 52 week wow than the high. This sector is supposed to be picking up in this company looks pretty decent. What can we expect as far as mergers or stock forecast for 2020? Pretty legitimate not asking for million dollar tickers...

Where are we and where are we going....

👍️0

czni 5 years ago

You saw that, yes.
thanks but I do not have a photographic memory unfortunately.

Looks like you were taken down.
Fast!
But we’re smarter than that

👍️0

czni 5 years ago

That’s why I love this board. You don’t have to deal with scammers or flippers or anybody trying to feed you a line just to buy end so they can dump. You guys have already been very hospitable. There’s a certain company farmer that is going to buy 11% of a biotech company. If we can find out the ticker symbol on this biotech company,
it’s worth about 180% in the first three days and a bunch more coming after.

Right now the biotech price is very low.

If we can keep it to just us for now The ones here that are interested can get in before the world finds out about it.
Trust me,
I spent four hours digging and digging to find this ticker.

Nobody is leaking it.

Come on guys,
dig a little bit with me.
I promise you it will be worth it!

I put a lot of time in. As soon as I find it I will share on this page. And only this page! It’ll be taken down by Monday so it needs to happen. Everybody takes 15 minutes.

With the experience reading this,
I have no question we can get this ticker symbol.

Monday morning we will be locked and loaded!

Oh yes!

👍️0

czni 5 years ago

Hey gang,
Im a quiet holder but have a question driving me crazy!

The MU wait for chips was so Ridiculous even after having this giant to do in Las Vegas.

Do you know the people that paid all around the world to go to Las Vegas just to hear that ticker symbol was not given out at that meeting?

You had to purchase his book in order to get it.

As soon as I dug it up,
I gave it out to everybody.

Now this big Pharma company whoever they are,
are getting ready to purchase 11% of a biotech company.

It has not happened yet but I’m looking for the ticker symbol for the biotech company.

The Pharma company is already out of reach but the biotech company There’s a couple of very important patents making the merger happen quicker.

Does anybody know the biotech company ticker symbol?

I need something that’s going to climb and keep climbing.

On a sidenote,
before my wife finds out I lost just about everything on the stock that should have gone to 50 plus wish i had known they had trouble with their CEO and the CFO having private meetings putting the company under investigation and stopping all Trading for over a month. It trades for 1/10000 of a penny now. I put everything on it!!!

. If you can throw that out to me, you could possibly change my marriage LOL.
Thanks very much and good skill to everyone!
The only job that I have ever had that did not look forward to the weekends!!! Happy hunting!
I dont have pm but please use it if you can. Happy Holidays!

Thanks gang

Sweet Virginia Breeze

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Nektar Therapeutics (NKTR)

Empower your portfolio: Real-time discussions and actionable trading ideas.

NKTR News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Form 8-K - Current report

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

NKTR Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Nektar Therapeutics (NKTR) News

Nektar Therapeutics (NKTR)

Empower your portfolio: Real-time discussions and actionable trading ideas.

NKTR News

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Form 8-K - Current report

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

NKTR Discussion

Your Recent History

Company

Business

Popular

Get The App